Inspiration Biopharmaceuticals names John Butler as ceo

Replaces Michael Griffith who takes position of cso

Inspiration Biopharmaceuticals, a US biopharmaceutical company focused on the development of treatments haemophilia, has appointed John Butler as ceo. He has replaced Michael Griffith, who has become chief scientific officer and remains company president.

Butler has joined Inspiration from Genzyme, which was acquired by Sanofi in April. While at Genzyme, he was most recently president of the company's rare genetic diseases business. He also led the company's renal, endocrinology, and cardiovascular businesses.

Prior to Genzyme, Butler held sales and marketing positions at Amgen and Hoffmann-La Roche.

You may also like

Manufacturing

CMC Biologics and Inspiration agree supply of IB1001

For the treatment and prevention of bleeding in haemophilia B patients
Packaging

ProMach Pharma presents new equipment at Pack Expo Las Vegas

Several new systems will be on exhibit for the first time, alongside other advanced processing and packaging equipment for pharmaceuticals, biopharmaceuticals, nutraceuticals, medical devices and more
Pharmaceutical

CPHI Frankfurt 2025 to welcome more than 60,000 pharma professionals with expanded focus on innovation and sustainability

Returning to Germany from 28-30 October, CPHI Frankfurt 2025 will unite the global pharmaceutical supply chain with more than 2000 exhibitors, six content theatres and new feature zones
Manufacturing

Continuous innovation: redefining the future of pharmaceutical manufacturing

In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
Pharmaceutical

Keystone Folding Box Co. unveils Key-Pak Plus

Designed to protect children and empower seniors, it achieves top U.S. safety ratings and meets global accessibility standards
Pharmaceutical

Bavarian Nordic launches chikungunya vaccine Vimkunya in the UK

The UK announcement of the recombinant vaccine follows recent approval by the MHRA in May 2025
Research & Development

Servier and IDEAYA Biosciences join forces to bring a promising new eye cancer treatment to patients across the globe

Servier and IDEAYA Biosciences have entered into an exclusive license agreement for regulatory and commercial rights to darovasertib outside the US
Subscribe now